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A B S T R A C T
The 5th Global Forum on TB Vaccines was held in New Delhi, India from 20 to 23 February 2018. This was the
largest Global Forum on TB Vaccines to date with nearly 350 participants from more than 30 countries. The
program included over 60 speakers in 12 special, plenary and breakout sessions and 72 posters. This Global
Forum brought a great sense of momentum and excitement to the field. New vaccines are in clinical trials, new
routes of delivery are being tested, novel assays and biomarker signatures are being developed, and the results
from the first prevention of infection clinical trial with the H4:IC31 vaccine candidate and BCG revaccination
were presented. Speakers and participants acknowledged the significant challenges that the TB vaccine R&D
field continues to face - including limited funding, and the need for novel effective vaccine candidates and tools
such as improved diagnostics and biomarkers to accurately predict protective efficacy. New solutions and ap-
proaches to address these challenges were discussed. The following report presents highlights from talks pre-
sented at this Global Forum. A full program, abstract book and presentations (where publicly available) from the
Forum may be found at tbvaccinesforum.org.
1. Why we need better TB vaccines
In the opening session, Soumya Swaminathan (World Health
Organisation, Geneva) noted the commitment and momentum resulting
from the 2015 United Nations Sustainable Development Goals (SDGs),
the End TB strategy that set targets to reduce the incidence rate of TB by
80% and TB deaths by 90% by 2030 compared to the 2015 figures, and
the 2017 WHO Global Ministerial Conference in Moscow. However the
burden of TB remains huge, with tuberculosis the 9th leading cause of
death globally, and the top infectious disease killer, and an estimated
1.7 billion, 23% of the world's population, estimated to be infected with
Mycobacterium tuberculosis (Mtb) [1]. In 2016, approximately 10.4
million new cases of tuberculosis disease (TB) occurred worldwide, of
which 90% occurred in adults [2]. The only licensed vaccine to prevent
TB, Bacille Calmette Guérin (BCG) is moderately effective in preventing
TB in infants and young children, but is unreliable in preventing TB in
adolescents and adults and has had no apparent impact on the global TB
epidemic. Speakers reiterated forcefully that new, more effective TB
vaccines, along with shorter treatment regimens and more accurate
diagnostics, will be essential to reach the ambitious targets set forth in
the SDGs and the End TB Strategy [3].
The general view at the Forum was that development of a new TB
vaccine that is better than BCG is possible and imperative to meet the
UN goals. It has been an oft-stated maxim in the field that infection with
Mtb fails to induce protection, yet 90% of latently infected individuals
remain disease-free [4,5]. The results from the H4/BCG revaccination
trial (see below) have renewed interest in the effects of BCG vaccina-
tion. When BCG gives protective efficacy against mortality, this can
persist for far longer than previously thought [6–9], BCG confers non-
specific protective efficacy via trained immunity [10], and exposure to
non-tuberculous mycobacteria may influence disease and vaccine effi-
cacy [11–13]. There is also increased interest in individuals who resist
conversion to positive in an interferon-gamma release assay, or who
convert and subsequently revert to negative [14–18].
Barry Bloom (Harvard School of Public Health, USA) gave the in-
troductory keynote address entitled “Why we need a vaccine to control
TB and what we need to learn to develop an effective vaccine”. He
noted the rationale for vaccines in controlling TB in LMIC eg. patients
need to see multiple providers before diagnosis is made, only 40%
completion of treatment and non-WHO standard treatments provided in
the private sector. He reviewed older studies indicating that healthy
nurses who were tuberculin positive and heavily exposed to TB were
over 90% protected against disease, and BCG was half as effective as
latent TB. He noted that in the South India BCG trial of 260,000 people,
which showed no protection against TB in any age group, a subset
analysis of those who were skin test negative for both human and non-
tuberculous mycobacteria showed significant protection, indicating the
need for new vaccines to protect beyond prior exposure to antigens to
protect against disease. While a great deal has been learned about im-
munology of TB from animal studies, for example the essentiality of
both CD4 and CD8 cells for protection, multiple immune mechanisms
have been found to exist in humans which differ from those in mouse
and even non-human primate (NHP) models. It is critically important to
identify immune responses that correlate with protection from infection
and disease in humans. Probably the best way to do this will be to
search for molecular markers of protection in studies in NHPs and from
bio-banked samples from human vaccine trials. It is likely that different
vaccine concepts, both live attenuated and subunit vaccines will con-
tribute to engendering and understanding protection in humans.
2. Modelling target indications and populations for new TB
vaccines
Richard White and Rebecca Harris (London School of Hygiene and
Tropical Medicine, UK) presented modelling data on the impacts of
potential indications and target populations, demonstrating that
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vaccine impact will vary based on the setting, prevalence of infection,
and manifestation (e.g., primary vs reactivation disease). Their mod-
elling shows that in most low and middle-income countries (LMICs) and
China, prevention of disease (POD) vaccines may have a faster and
greater impact than vaccines developed for prevention of infection
(POI), before 2050 [19], [Harris et al. 2018 in press]. In more trans-
mission-driven epidemics (eg. India), efficacy for POI or POD could
substantially impact the TB epidemic, assuming that POI leads to POD
in those who would normally advance to disease in the absence of
vaccination. In aging, reactivation-driven epidemics like in China, post-
infection vaccines may have the greatest impact [19].
Vaccines targeted to adolescent/adult populations in LMICs may
have a greater and more rapid impact than neonatal vaccination, before
2050, and may be cost effective even at a vaccine efficacy (VE) of 20%
for 5 years duration of protection. Furthermore, an appropriate vaccine
that targets adults and adolescents may be as or more effective in re-
ducing TB incidence in children below 4 years of age than a childhood
vaccine, as preventing TB in adolescents and adults, the main trans-
mitters of TB, would prevent transmission to infants and young chil-
dren.
3. Vaccine strategies to tackle drug resistant TB
A vaccine to prevent drug-resistant as well as drug-sensitive TB is
also a priority. TB accounts for more than one in four of the anti-
microbial resistance (AMR) fatalities per year. Although 56 million TB
cases have been successfully treated in the last 15 years, only about half
of the multi-drug-resistant cases in India, Pakistan and the Russian
Federation have a successful treatment outcome. In South Africa, from
2011 to 2014, 74% of XDR-TB patients were deemed programmatically
incurable and>50% of these were discharged home, further spreading
the XDR pathogen [20]. Transmission of MDR and XDR strains is a
public health problem, and factors such as (i) inadequate treatment, (ii)
early discharge of incurable TB patients from hospitals, and (iii) poor
adherence to timely treatment due to increased cost and side effects are
likely to increase the MDR/XDR-TB burden in the coming years.
Gavin Churchyard (Aurum Institute, South Africa) presented pos-
sible vaccination strategies to control the rising burden of multidrug-
resistant (MDR) and extensively drug-resistant (XDR) TB. Since the
molecular changes that result in drug resistance are highly unlikely to
alter antigenic proteins, TB vaccine candidates that can target drug
susceptible pathogens should be equally efficient against drug resistant
organisms. Therapeutic vaccines also have the potential to shorten
treatment, reduce treatment failure and ultimately prevent recurrence.
RUTI (a vaccine containing cell wall fragments of Mtb) and M. vaccae
have shown some clinical promise, but studies to date have been small
and of variable quality [21]. New candidates such as ID93 + GLA-SE
[22] and HVJ Envelope/HSP65 DNA + IL-12 DNA with either Granu-
lysin or Ksp37 [23,24] have shown preclinical therapeutic efficacy,
while an Ag85A DNA vaccine gave mixed results [25–27]. Therapeutic
value has also been explored for the Ag85B DNA vaccine [28]. Overall,
MDR-TB patients may be an ideal group in which to evaluate ther-
apeutic vaccine candidates due to the favourable benefit-risk balance.
4. Novel approaches and strategies to maximize the probability of
success
Vaccine development is risky and expensive, and resources are
limited. Georges Thiry (Aeras-TBVI Joint Working Group on Stage
Gates, France) provided an overview of ‘stage gate criteria’ that have
been developed to help promising TB vaccine candidates to advance
through the stages of TB vaccine development. These stage gates are
part of a portfolio management process intended to reduce risk, in-
crease the overall probability of success, and direct limited resources
toward the most promising candidates.
Several strategies and approaches are being undertaken to minimize
cost and accelerate development of potential candidates. Adaptive trial
designs, in combination with other new tools, may act as a proof-of-
concept strategy and down-selection tool to triage prevention of disease
(POD) vaccine candidates at an early stage, before large, long and ex-
pensive efficacy trials are initiated. Several trials, such as the VPM1002
trial in India, the H56:IC31 trial in South Africa and the ID93+GLA-SE
trial in South Africa, are testing the ability of vaccines to prevent re-
current TB disease (POR) in TB patients who have successfully com-
pleted treatment for active TB. Still others, including H4:IC31 and DAR-
901 are being tested in trials to evaluate whether they can prevent
infection (POI) or established latent TB infection (see 3.1 TB vaccines in
clinical development).
More work is required to provide improved animal models for
down-selection of vaccine candidates and parallel challenge studies,
including an urgent need for a human challenge model. So far, every
potential TB vaccine candidate has been tested in animal models before
progression to humans, but it is unclear whether the currently available
preclinical models predict efficacy in humans. A safe human challenge
model might greatly accelerate the clinical testing of new TB vaccines,
but while an auxotroph might elicit poor immune responses, a persis-
tent strain might be too dangerous to test. To this end, Eric Rubin
(Harvard T. H. Chan School of Public Health, USA) and colleagues are
exploring ways to modify potential vaccine candidates with (i) in-
ducible killer switches for self-destruction, (ii) requirement of non-ca-
nonical amino acids for growth/survival, and (iii) addiction to specific
antibiotic(s). Their novel M. smegmintis and tubercumint candidates
expressing volatiles such as methyl salicylate and 2-aminoacetophe-
none might aid in quantitating vaccine presence in the human lung.
These approaches will be tested soon in NHPs.
Ann Ginsberg (Aeras, USA) discussed potential options to enrich
cohorts for smaller, quicker and more efficient TB vaccine efficacy
trials. Phase 3 Prevention of TB Disease efficacy trials could readily
require> 10,000 participants to be enrolled with long follow-up per-
iods to obtain a sufficient number of TB cases to power statistical
comparisons. While groups such as miners, prisoners, patients with
diabetes and people living with HIV are at higher risk for TB disease,
and therefore targeted enrolment of such individuals could reduce
study sizes, these cohorts represent ethical and/or immunological
challenges. In a very feasible approach to reducing sample size and
thereby costs, the current M72 Phase IIb study (TB-018) has enrolled
only QFT-positive adults to reduce study size, with 3573 participants to
be followed for 3 years. Other potentially useful approaches include the
preferential enrolment of healthcare workers [29–31] or household
contacts of active TB patients [32,33], who are at significantly higher
risk of developing disease.
Sriram Selvaraju (National Institute for Research in Tuberculosis,
India) reported that in this Indian setting, excluding co-incident cases
diagnosed in the first month after recruitment, 16/1385 healthy
household contacts developed TB disease, with most diagnosed in the
first 6–12 months of follow-up. Medical and nursing trainees in Indian
hospitals are also at high risk of developing TB. Aarti Avinash Kinikar
(Bryamjee Jeejeebhay Government Medical College, Pune, India)
showed that medical residents had a relative risk of infection of 2 and
that over one third of trainees developing incident TB reported TB ex-
posure within the hospital setting; thus this group would really benefit
from a preventive TB vaccine.
5. Clinical development of new TB vaccines
5.1. TB vaccines in clinical development
Ann Ginsberg (Aeras, USA), provided an overview of TB vaccines in
clinical development, noting that we stand at a critical juncture in TB
vaccine development. At the time of the 5th Global Forum, there were
13 candidates in the clinical vaccine development pipeline (see Fig. 1),
including the M72/AS01E candidate from GlaxoSmithKline (GSK) for
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which efficacy results from the multinational Phase IIb POD study are
expected in mid-2018 and five additional vaccine candidates whose
developers have recently reported or are expected to report efficacy
results in POD, POR or POI trials in the next two to three years
(H4:IC31, BCG revaccination, VPM1002, M. vaccae and DAR-901). Yet
there is a relative lack of diversity in the pipeline with respect to types
of immune responses being generated by design, and future vaccine
candidates may require new antigens, new modes of delivery or dif-
ferent hypothesized mechanisms of immune protection.
Mark Hatherill (South African Tuberculosis Vaccine Initiative
(SATVI), South Africa) presented exciting efficacy results on the first
POI study, which took place in South Africa, sponsored by Aeras
(NCT02075203). Nine-hundred and ninety QFT-negative adolescents
who had undergone neonatal BCG vaccination were enrolled and ran-
domised equally into each of three study arms and received the H4:IC31
candidate vaccine, BCG revaccination or saline. The research team
showed that BCG revaccination, and to a lesser extent the H4:IC31
subunit vaccine, prevented sustained conversion of the Interferon-
Gamma Release Assay (IGRA) (positive being defined as> 0.35IU/ml
of IFNγ in the QuantiFERON-TB (QFT) Gold Test sustained for at least 6
months), compared to saline placebo administration to QFT-negative
adolescents [34]. The team demonstrated that BCG provided 45.4%
vaccine efficacy (95% confidence interval 6.4–68.1), and H4:IC31
provided 30.5% vaccine efficacy (80% confidence interval 3.0–50.2)
with no statistical significance at the 95% confidence interval level
[34]. This finding is a momentous achievement for the field and opens
the doors for future studies of correlates of protection from Mtb infec-
tion.
Sustained QFT-conversion was the secondary endpoint of this study,
whereas there was not statistically significant efficacy against the pri-
mary endpoint of initial QFT-conversion. The authors observed a
number of QFT-converters who initially converted but then later re-
verted, highlighting the “zone of uncertainty” regarding repeat mea-
sures of QFT values between 0.2 and 0.75 IU/ml as presented by Elisa
Nemes (SATVI, South Africa) [34]. This trial highlights the importance
of standardising laboratory assays and storing samples from all vaccine
clinical efficacy trials for future possible correlates research. These
encouraging results now need to be repeated in other populations and
demographic settings. First results from another POI study, using DAR-
901, are expected later in Q4 2019 [35] (see below).
Prasad Kulkarni (Serum Institute of India, India) presented progress
with VPM1002, a recombinant BCG designed to be both safer and more
immunogenic than parental BCG, which is being tested in a Phase III
post-exposure study in India to prevent recurrent TB disease in adults
who have completed successful TB treatment (NCT03152903).
VPM1002 is also being progressed to a Phase III prime study in HIV-
negative and -positive infants in Africa (NCT02391415) [36]. These
trials build on successful Phase I trials in Germany and South Africa and
a Phase IIa trial and Phase II trial in newborn infants in South Africa
[37,38]. Kavita Singh (Multi Vaccines Development Program, India)
discussed the potential of TB vaccines to prevent disease in the healthy
household contacts of TB patients. A Phase III trial of VPM1002 (single
vaccination) and heat-killed Mycobacterium indicus prani (MIP; two
vaccinations four weeks apart) compared to placebo is being planned,
which would have 4000 participants per arm. Incident cases will be
captured between 2 and 38 months after screening, and im-
munogenicity assessed in some of the participants. The MIP vaccine was
safe when used as a therapeutic vaccine in combination with drug
treatment in sputum-smear positive pulmonary TB patients [39].
Pere-Joan Cardona (Institut d’Investigació en Ciències de la Salut
German Trias i Pujol, Spain) presented data on the development
pathway of oral delivery of M. manresensis, a water-borne myco-
bacterium related to M. fortuitum [40], to prevent TB disease. The un-
derlying hypothesis is that a PPD-specific regulatory T cell response
reduces IL-17 production to limit neutrophil infiltration into the lungs,
preventing the immunopathology associated with active TB disease. A
Phase I study has demonstrated an acceptable safety profile and in-
duction of an antigen-specific regulatory T cell profile in adults [41].
The candidate, classified as a probiotic food supplement, is now being
tested in Phase II efficacy studies to prevent active TB disease in adults
Fig. 1. Global clinical pipeline of TB vaccine candidates. Information on candidates in clinical development is self-reported by vaccine sponsors, coordinated by the
Working Group on TB Vaccines and was updated in September 2017 by Aeras. Image courtesy of Aeras.
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in Georgia (NCT02897180).
Aldar Bourinbaiar (Immunitor LLC, Mongolia) presented data from
a Phase III study of oral administration of heat-killed M. vaccae (for-
mulated as an oral tablet) as an adjunct to conventional TB therapy to
treat active TB disease (NCT01977768). Two Phase II trials have shown
therapeutic potential alongside conventional TB therapy in adults
[42,43]. Interim results from the randomised (2:1) Phase III trial of 100
patients receiving the V7 M. vaccae vaccine and 52 who were given
placebo showed that after just one month 68% of those receiving V7
had mycobacterial clearance in sputum smears compared to 23.1% of
the placebo group, regardless of whether they had drug-sensitive or
drug-resistant TB. The full Phase III results and the associated me-
chanisms of action will be of interest to the community as a whole.
There is a lot of interest in the clinical development of MTBVAC, the
first attenuated live Mtb vaccine in clinical trials. Carlos Martin
(University of Zaragoza, Spain) discussed the mechanism of attenuation
and protection by MTBVAC, a Mtb devoid of fad26 (leads to loss of
PDIM) and phoP, a transcription factor regulating major Mtb virulence
genes (preventing ESAT6 secretion). MTBVAC induced immunogenic
responses in animal models, with improved protective efficacy relative
to BCG [44,45], and was tested for safety and reactinogenicity in
Lausanne, Switzerland [46], Michele Tameris (South African Tubercu-
losis Vaccine Initiative, South Africa) presented results from a Phase I
study of MTBVAC with a safety run-in in adults [46], and safety and
immunogenicity results from a dose-escalation in infants vaccinated at
birth (NCT02729571). MTBVAC was well tolerated in all dose groups
and induced specific vaccine dose-dependent immune responses. In-
terestingly, up to 78% of vaccinated infants converted to a positive QFT
at 6 months post vaccination, in a dose-dependent manner. This is likely
due to administration of MTBVAC rather than natural infection, as
MTBVAC still secretes CFP-10 into culture filtrate [47]. However, as
protocol and South African guidelines dictate, children under 5 years of
age who were QFT-positive were provided IPT. At 12 months post
vaccination,> 60% of QFT-converters had reverted. This vaccine can-
didate is scheduled to advance into both adult and infant clinical trials
in 2018, in which QFT conversions will be further investigated.
Tracey Day (Infectious Disease Research Institute, USA), presented
data on the clinical development of the recombinant protein antigen
ID93 combined with the TLR-4 agonist adjuvant GLA-SE, a glucopyr-
anosol lipid A stable nano-emulsion. A Phase Ia clinical trial in adults in
the US demonstrated an acceptable safety profile and induction of both
antigen-specific CD4+ T cell responses and multi-functional antibody
responses capable of antibody-dependent cellular phagocytosis
(NCT01599897). A Phase Ib study in Mtb-infected and uninfected
adults in Cape Town, South Africa, demonstrated safety and robust
antigen-specific CD4+ T cell and antibody responses (NCT01927159)
[48]. Interestingly, CD4+ T cell responses to each of the four ID93
subunit proteins showed diverse functionality profiles, as measured by
cytokine expression profiles, suggesting that each of the four antigens
may be expressed at different stages of the Mtb life-cycle, which induce
immune responses with corresponding stages of T cell differentiation
[48]. The authors suggest this breadth of T cell differentiation to anti-
gens may be important in expanding the diversity of the current TB
vaccine pipeline. Finally, Day presented preliminary immunogenicity
data on the use of ID93 + GLA-SE in a Phase IIa study evaluating a
prevention of recurrence vaccination strategy in South African adults
who had successfully completed treatment for active TB
(NCT02465216). Vaccination of this group was well-tolerated, and in-
duced antigen-specific, multifunctional CD4+ T cell and humoral re-
sponses. Safety and immunogenicity results from this study are ex-
pected to be published later in 2018. Ongoing trials are also evaluating
liposomal and lyophilized adjuvant formulations. Planned studies will
assess safety, immunogenicity, and efficacy for prevention of infection,
prevention of recurrence, and immunotherapeutic strategies.
New viral vectors may have promise for delivery of TB antigens.
Marina Stukova (Research Institute of Influenza, St. Petersburg, Russia),
presented results of a Phase I study of vaccination with TB/FLU-01L, a
replication-deficient influenza A virus vector expressing ESAT-6, in
QFT-negative, previously BCG-vaccinated adults (NCT02501421). Two
doses, delivered 21 days apart by either intranasal or sublingual routes,
were well-tolerated, and induced both CD4+ and CD8+ T cell re-
sponses, with no viral shedding detected after vaccination. A Phase IIa
trial in QFT-positive individuals is ongoing. Another viral vector, the
adenovirus-based TB vaccine candidate expressing Ag85A (Ad5Ag85A)
developed by McMaster University, has entered into a Phase I clinical
trial testing aerosol administration (NCT02337270).
DAR-901, consisting of inactivated M. obuense (a non-tuberculous
mycobacterium), was discussed by Ford von Reyn (Dartmouth, USA).
Pre-clinical studies have demonstrated safety and superior protective
ability over BCG as a boost to BCG in animal models [49]. A Phase I
trial in BCG-vaccinated adults demonstrated safety and immunogenicity
in HIV-negative, HIV-positive, IGRA-negative and IGRA-positive in-
dividuals [35]. Results from a Phase IIb POI randomised controlled trial
in 650 IGRA-negative Tanzanian adolescents will be available in Q4
2019 (NCT02712424), and DAR-901 is expected to advance to a Phase
III POD trial in 2020.
5.2. Community engagement in vaccine trials
To carry out such vaccine trials in the community requires more
than good vaccine trial design. Moses Zimba (Centre for Infectious
Disease Research, Zambia) discussed the importance of Good
Participatory Practice (GPP) in trial participant retention, reducing
stigma and misconceptions, educating communities and generating
advocacy. GPP Guidelines for TB Vaccine Research have been devel-
oped in part by Aeras, and remind researchers of the importance of
coordinating retention events for participants, scheduled home visits,
regular visit reminders, after-hours visit options and provision of other
health care related services at the same facility (e.g., family planning
clinic and social care services). The benefits and impact from commu-
nity engagement activities is clear. At the site where Zimba works, the
study retention rate was 97.2%, only 2% of study visits were missed,
and issues with stigma and discrimination were quickly resolved.
6. Improving the effectiveness of new vaccines
BCG given by the intradermal (ID) route demonstrates protective
efficacy against systemic TB infection during infancy/early childhood,
but fails to provide consistent, high-level protection against pulmonary
TB in adolescents and adults [50]. One possible explanation is that the
ID route does not induce sustained T cell responses in the lung that may
be critical for pulmonary TB [51]. Robert Seder (National Institute of
Allergy and Infectious Diseases and National Institute of Health, USA)
and his collaborators assessed how the route and dose of BCG influ-
enced TB-specific T cells in the lungs of NHP. NHP were immunized by
the standard ID route or intravenous (IV), aerosol (AE) or a combina-
tion of ID/AE routes. AE and IV administration increased the fre-
quencies of multi-functional (IFNγ, TNFα, IL-2 and IL-17) PPD-specific
CD4+ T cells by 10–100 fold respectively in bronchoalveolar lavage
(BAL) compared to BCG ID. Moreover, IV immunization also induced a
higher frequency of CD8+ T cells that were sustained for at least 4
months after IV immunization. Further, BCG administered IV induced a
profound change in the ratio of macrophages and T cells in BAL. These
data establish how the magnitude, quality, breadth and durability of
TB-specific T cells in the lung can be strikingly increased by BCG ad-
ministered by the IV route.
Coupled with the results of ID BCG revaccination as part of the
H4:IC31 POI trial, there may be further interest in delivering BCG by
alternative routes. Frank Verreck (Biomedical Primate Research Centre,
The Netherlands) discussed work extending his earlier demonstration of
superior protection in NHPs to Mtb challenge if BCG were administered
via the pulmonary mucosal (PM) route as compared to ID [51]. Post
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infection, IGRA conversion in NHPs vaccinated via the PM route was
delayed compared to the ID route. The PM route also resulted in re-
duced lung pathology and draining hilar lymph node involvement. This
route of delivery improved protection from both high-dose and re-
peated ultra-low dose Mtb challenges in NHPs.
Tom Scriba (SATVI, South Africa) discussed vaccination following
mycobacterial exposure, which is likely to be of greater importance if
new TB vaccines are administered to adolescents or adults. Earlier
studies of the protection induced by BCG showed greatest protection in
those children who were tuberculin skin test (TST) negative [52]. Ex-
posure to non-pathogenic mycobacteria in the environment could in-
duce a protective response not improved with vaccination (“masking”)
or stop the replication of BCG so that it cannot induce protection
(“blocking”) [53]. Natural immunity can be induced by exposure to
Mtb, and the challenge is to improve on this by vaccination. BCG re-
vaccination is well-tolerated [54] but it is clear that prior mycobacterial
sensitisation by BCG or by infection with Mtb can have marked effects
on the immunogenicity of new TB vaccines [55]. As up to 50% ado-
lescents in some countries have latent TB infection (LTBI) [56], and
BCG is given to most infants, improved pre-clinical models are required
to study how novel vaccines perform in pre-sensitised animals.
Gil Diogo of the EMI-TB consortium (St George's, University of
London, UK) discussed new delivery systems for TB vaccines: Bacillus
subtilis spores and Yc-NaMA nanoparticles both coated with a fusion
protein FP1 consisting of Ag85B, ACR and HBHA antigens of Mtb.
Mucosal delivery of either Spore-FP1 or Nano-FP1 as a boost to mice
primed with subcutaneously-delivered BCG showed superior B- and T-
cell activation and significantly reduced bacterial burdens.
7. Filling the development pipeline: new TB vaccine candidates
7.1. Recombinant BCG
Matthias Groschel (Institut Pasteur, France) discussed how re-
combinant BCG (rBCG) expressing M. marinum ESX1 [57] promotes
cytosolic access [58] for superior immune signalling in THP1 cells in
vitro and in mice in vivo. This live attenuated strain, by accessing the
cytosol, can activate the cGAS/STING/TBK1/IRF-3/type I interferon
axis and AIM2-mediated NLRP3 inflammasomes, helping to control
virulence and increase protection through activation of both CD4+ and
CD8+ specific T cells.
7.2. Live saprophytic vaccines
Sangeeta Bhaskar (National Institute of Immunology, India) dis-
cussed the protective immune-therapeutic potential of M. indicus pranii
(MIP) and the underlying immune mechanisms in the guinea pig model.
MIP is a saprophytic mycobacterium expressing several important
mycobacterial antigens with considerable homology to virulent Mtb
[59]. They too evaluated different routes of delivery and found the
aerosol route to be most effective with potent lung immune responses,
resulting in faster elimination of Mtb when given as an adjunct to
chemotherapy. MIP has also shown potential protective efficacy when
given as a booster after BCG vaccination in animal models of TB.
7.3. Attenuated vaccines
As discussed above, MTBVAC, a live, attenuated Mtb strain, is in
clinical trials, but other live attenuated Mtb vaccines are in preclinical
development. Deepak Kaushal (Tulane National Primate Research
Center, USA) discussed the improved protection obtained using stress-
response deficient attenuated Mtb compared to BCG with enhanced
recruitment of proliferating CD4+ and CD8+ T cells to the lymphoid
follicles and lungs. Bacterial burdens were three logs lower in NHPs
vaccinated with MtbΔsigH compared with BCG [60]. Such animals also
showed diminished granulomatous pathology. No pulmonary TB-like
symptoms were seen among the NHPs vaccinated with MtbΔsigH [61],
although these animals did develop HIV-like symptoms when infected
with SIVmac239.
7.4. Viral and nucleic acid-based vaccines
Viral vectors promote efficient gene transduction and intracellular
antigen presentation [62]. Aurelio Bonavia (Vir Biotech, USA) pre-
sented preclinical data obtained with VIR-2020, a novel, human atte-
nuated CMV prophylactic vaccine candidate. Compared to controls, the
rhesus CMV ortholog vaccine showed an overall 70% reduction in TB
infections/disease (lung and extra-pulmonary disease) in NHPs. There
was no disease in 41% of animals by CT scan and necropsy [63].
Stephane Leung-Theung-Long (Transgene SA, France) showed that
the efficacy of chemotherapy against Mtb in a murine model was sig-
nificantly improved by co-administration of the MVA-based
MVATG18598 therapeutic vaccine carrying 10 antigens spanning ac-
tive, latent and resuscitation phases of Mtb infection [64]. Mice sub-
cutaneously vaccinated with MVATG18598 showed both Th1-asso-
ciated T-cell responses and cytolytic activity against all 10 Mtb
antigens. In combination with chemotherapy in chronic post-exposure
murine models, this vaccine helped reduce bacterial burden sig-
nificantly in the lungs. Concomitantly, an increase of the frequency of
IFNγ-producing T-cells and production of specific antibodies were ob-
served. It also reduced disease relapse by 30–40%, which is another
important clinical goal for a therapeutic vaccine.
Agnes L. Chenine (Aeras, USA) discussed the immunogenicity and
efficacy conferred by ChAd3-5Ag + MVA-5Ag prime-boost regimens in
NHPs challenged with virulent Mtb 12 weeks after the final vaccination.
Different routes of delivery were evaluated, including aerosol, par-
enteral, and heterologous parenteral prime-aerosol boost regimens.
NHPs vaccinated parenterally showed the highest T cell response in
blood (PBMCs) while animals vaccinated via aerosol showed the
highest response in BAL. Gross pathology, bacterial burden, and PET/
CT were evaluated as efficacy endpoints. Despite the induction of a
robust T cell response, no significant protection was observed in any of
the vaccinated groups.
Conventional and self-amplifying mRNA-based vaccines have been
tested in various preclinical animal models, including NHPs, and Jeffrey
Ulmer (GSK Vaccines, USA) discussed results showing their ability to
elicit potent T-cell and antibody-based immune responses. Several
mRNA-based vaccine candidates are currently being evaluated in
human clinical trials.
8. Biomarkers and correlates
The lack of a validated biomarker or correlate of protection from TB
remains a major impediment to the development of an effective vac-
cine. Biomarkers would be invaluable in demonstrating relevant im-
munogenicity, down-selecting vaccine candidates, and thereby con-
tributing to stage gates, reducing the time-scale of clinical trials and
optimising vaccine dose. However, the field is fraught with challenges
including the rarity of head-to-head testing which is mainly limited to
animal models, that biomarkers may be vaccine-specific, and the cir-
cular issue of the need for biomarkers to design rationally rather than
empirically a protective vaccine, but the need for a protective vaccine
to identify biomarkers. Hazel Dockrell (London School of Hygiene and
Tropical Medicine, UK) outlined ways in which we can learn in the
interim through the study of: a) individuals who do and do not develop
disease in vaccine trials, b) exposed contacts who do and do not develop
disease, c) individuals with active disease compared to latent infection,
d) latently infected individuals with long-term non-progression, e) TB
cases before and after treatment and f) treated TB cases who do and do
not relapse.
Biomarkers research conducted by the TBVAC2020 consortium in-
cludes identifying, testing, evaluating and prioritising the most
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promising human biomarkers, but also bridging with animal models
[65]. Key samples and assays include (i) peripheral blood mononuclear
cells (PBMC) for flow cytometry, intracellular cytokine staining (ICS),
ELISpot and the functional mycobacterial growth inhibition assay
(MGIA); (ii) serum for antibody ELISAs and multiplex cytokine/che-
mokine assays; and (iii) RNA analyses. IFN-γ ELISpot responses and
Ag85A-specific antibody responses were recently identified as corre-
lates of reduced risk of disease in BCG vaccinated South African infants,
and activated HLA-DR+ T cells as a correlate of increased risk of dis-
ease [66]. Such findings now require replication. Interestingly, a
follow-up study from the same cohort presented by Iman Satti (Uni-
versity of Oxford, UK) found that these immune parameters did not
correlate with risk of infection, as defined by QFT conversion in the
absence of disease. MGIAs have the potential to provide the best insight
into biosignatures. Although they can be technically complex [67,68],
improved control of mycobacterial growth was detected following BCG
vaccination in both UK infants [69] and historically vaccinated adults
using the direct PBMC MGIA, consistent with the findings of Fletcher
et al. [70].
Stefan H.E. Kaufmann (Max Planck Institute for Infection Biology,
Germany) spoke on the identification of predictive biosignatures to
improve TB vaccine development, with a focus on whole blood tran-
scriptomic signatures, the most advanced area of TB biomarker re-
search. Such signatures can be applied to stratify individuals at high
risk of progression to disease (which may represent those with incipient
subclinical TB), significantly reducing the size, duration and cost of
clinical vaccine trials. Zak et al. recently described a 16-gene signature
able to predict progression from LTBI to active disease with 66% sen-
sitivity and 81% specificity within a year of TB diagnosis, which was
validated in independent cohorts of South African and Gambian pro-
gressors and controls from a GC6 household contact study [71]. This
signature may be further minimised by introducing pair ratios to just 2
genes; such a signature has been applied to the GC6 and adolescent
cohorts with a specificity of 70–80% [72]. The transcript and a meta-
bolite-based signature developed as part of the GC6 initiative were both
able to predict progression to active TB in household contacts up to 12
months prior to the onset of clinical disease. These bio-signatures may
be useful for stratification of study participants for clinical trials and
may be harnessed for the targeting of preventative therapy before the
development of clinical disease and subsequent transmission. The
Correlate of Risk Targeted Intervention Study (CORTIS) in South Africa
led by the South African TB Vaccine Initiative (SATVI) aims to test the
prognostic performance of these signatures in healthy individuals, as
well as the efficacy of targeted preventive therapy on development of
TB disease [73].
A key theme emerging from the biomarkers and correlates sessions
was the need for testing in cohorts that reflect real-world variability
within and between populations. In addition to the differences in how
European and African infants respond following BCG vaccination de-
scribed by Dockrell, Jeffrey A Tornheim (Johns Hopkins University
School of Medicine, USA) described how gene expression profiles of
paediatric TB cases and matched controls from India showed little
overlap with those published outside of India. It is clear that biomarker
evaluation should expand beyond the African subcontinent and India to
other TB endemic regions in order to develop universal biomarker
signatures. Exposure to non-tuberculous mycobacteria (NTM) is im-
portant [74,75] but not the whole story; particularly when confronted
with differential responses in immunologically naïve infants. Additional
contributing factors may include imprinting and epigenetic changes
originating from the mother, other childhood vaccinations, nutritional
status, and viral or helminth infections [76–79].
In addition to biomarkers of risk of disease or progression from la-
tent to active disease, biomarkers of conversion to latent infection in
healthy exposed household contacts may be useful in directing POI
vaccine development. Kamakshi Devalraju (Bhagwan Mahavir Medical
Research Centre, India) presented a study of almost 1000 household
contacts followed up for 2 years, 381 of which were LTBI-negative at
enrolment. The frequencies of NK cells and memory-like NK cells
(CD3−CD56+CD27+CCR7+) at baseline were higher in those who did
not convert to LTBI compared with those who did and may therefore
represent a biomarker of protection from infection.
9. Basic research: new approaches to vaccine design
Basic research is fundamental to progress in the TB vaccine field and
needed to identify new vaccine candidates. Understanding the biology
of Mtb such as the biochemical pathways critical for its survival and
pathogenesis, the host immune response, and the host-pathogen inter-
action are essential in identifying novel targets for both therapeutic and
vaccine interventions. One major theme of the basic research presented
at the 5th Global Forum was the mechanisms by which Mtb manip-
ulates the host cellular response through immune evasion or modula-
tion. For example, Ekansh Mittal (Washington University School of
Medicine, USA) discussed how the Mtb secreted virulence factor EsxH
(TB10.4) impedes antigen presentation and transfer to bystander cells
by altering exosomes, thus impairing the ability of CD4+ T cells to
recognise infected macrophages.
Buka Samten (University of Texas Health Science Center, USA)
presented data showing significantly higher levels of cyclic AMP
(cAMP) in PBMC from TB patients compared with latently infected
individuals. Elevated cAMP was associated with inhibition of IFN-γ
production by T cells through the protein kinase A (PKA) type I
pathway via suppression of transcription factors that regulate IFN-γ
[80]. A further protein kinase, PknG, was shown to mediate persistence
under latency-like conditions in vitro via phosphorylation of the meta-
bolic regulator GarA, and contributed to stable granuloma formation in
a guinea pig model as presented by Mehak Zahoor Khan (National In-
stitute of Immunology, India) [81]. Another approach reported by Di-
pendra Mitra, All India Institute of Medical Sciences, is to target the
checkpoint inhibitor PD-1 to enhance the efficacy of therapeutic TB
vaccines. Both the regulatory T cell and the PD-1 axes are involved in
actively suppressing T cell responses in tuberculosis, and blocking PD-1
restores IFNγ and TNFα production. Giving anti-PD-1 antibodies can
reduce the bacterial burden in Mtb infected mice, particularly if this is
combined with drug therapy, offering the prospect of a novel host-di-
rected therapy.
An improved understanding of the immune response to Mtb infec-
tion is also critical to inform vaccine strategies. Cheleka Mpande
(University of Cape Town, South Africa) presented the kinetics of Mtb-
specific CD4+ T cells in a longitudinal cohort of recent QFT converters,
revealing highly activated specific CD4+ T cells during acute infection
followed by an increase in resting Mtb-specific central memory T cells
(TCM) during established infection. Mtb-specific stem cell-like memory
(Tscm) CD4+ T cells were also induced during primary infection, and
displayed chemokine receptor profiles consistent with memory Th1/
Th17 cells and expressed cytotoxic effector functions during established
infection [82]. Polymorphisms in TLR genes have recently been asso-
ciated with susceptibility to TB and idiopathic pulmonary fibrosis. Ja-
veed Ali Shah (University of Washington, USA) described how the Toll
interacting protein (TOLLIP) deficiency allele, rs5743854, is associated
with decreased expression of long non-coding RNA (lncRNA) TOLLIP-
AS1 expression, BCG-specific memory phenotypes and increased TB
susceptibility [83–85].
David Lewinsohn (Oregon Health & Science University, USA) spoke
on immune responses generated via the ‘non-classical’ presentation of
antigens through receptors that are highly conserved in humans. In
some cases these antigens are non-protein antigens. Donor-unrestricted
T cells (DURTs) include HLA-E- or CD1-restricted T cells, Mucosal
Associated Invariant T (MAIT) cells, natural-killer T-cells (NKT cells)
and γδ T cells [86]. The diversity of MHC class I and II alleles and the
TCR means that conventional T cells of each host may recognise dif-
ferent peptides, and that the immunodominant T cell antigens for any
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infection cannot be generalised between individuals. Furthermore,
there is an inherent risk of pathogen escape by antigenic variation.
DURTs, however, recognise their antigens through highly-conserved
molecules present among all humans, offering attractive candidates for
vaccine targeting [86]. Although this is a relatively new field, there is
already evidence accumulating for enrichment of MAITs and CD1-re-
stricted T cells in the lung during Mtb infection and of DURTs facil-
itating control of Mtb via polycytotoxic functions [87,88]. Knock-out
and adoptive transfer studies indicate that DURTs can be protective in
mice [89,90], and there have been two preclinical vaccine studies de-
monstrating modest levels of protection [91]. Ongoing studies are in-
vestigating whether DURTs are induced following BCG vaccination and
whether they have memory.
Interest in vaccine-induced memory has expanded beyond T cells.
Maziar Divangahi (McGill University, Canada) discussed how we can
harness the power of innate immunity in vaccines against TB via the
reprogramming of haematopoietic stem cells (HSCs) [92]. He examined
how BCG-IV vaccination ‘educates’ HSCs via epigenetic reprogramming
that can be transmitted to myeloid-committed progenitors to generate
‘trained immunity’ with sustainable protective capacity against TB. He
also discussed how identifying the protective signature of trained im-
munity will lead to a novel roadmap for developing TB vaccines. Chang
Ook Park (Yonsei University, South Korea) talked about tissue resident
memory T cells (TRM), cells that have also become of increasing in-
terest to immunologists over the last few years. Skin TRM cells that co-
localise with dendritic cells rapidly produce effector cytokines pro-
tecting against infection, as shown in a model of skin infection with
Candida. Mucosal vaccination with BCG also generates TRM in the
lungs of mice, which protect against TB [93].
10. The importance of political commitment, partnerships and
resources in vaccine development
The presentations at the 5th Global Forum on TB Vaccines demon-
strated the significant scientific progress being made, and there was a
sense of excitement and optimism, as new data was announced and
new, transformative approaches to R&D were presented and discussed.
But it was also recognized that political commitment, financial re-
sources, and partnerships and collaborations will be essential to sustain
and build on this momentum. During the Opening Session and
Inaugural Ceremony, Sunil Khaparde (Deputy Director General of TB,
Ministry of Health & Family Welfare, India), Preeti Sudan, (Secretary,
Department of Health and Family Welfare and Department of Health
Research, and Director General, Indian Council of Medical Research,
Ministry of Health & Family Welfare, India) and Anupriya Patel
(Honourable Minister of State, Ministry of Health & Family Welfare,
India), expressed the commitment of the Government of India to ad-
dressing the TB epidemic through a comprehensive approach that in-
cludes new approaches to improve services and care to those impacted
by TB, and investing in R&D for new TB vaccines. Renu Swarup (Senior
Advisor, Department of Biotechnology, Ministry of Science and
Technology, India) and Ashutosh Sharma, (Secretary, Department of
Science & Technology and Department of Biotechnology, Ministry of
Science and Technology, India), reiterated India's commitment to
ending TB, reviewed India's investment in R&D infrastructure and
human resource capacity, and discussed the importance of partnerships
and collaboration across sectors, noting that the public sector, private
sector, academics and civil society all have important roles in the re-
search and development of new TB vaccines. Soumya Swaminathan
(Deputy Director General, WHO, Switzerland), and Poonam Khetrapal
Singh (WHO Regional Director for South-East Asia, India) discussed the
importance of new TB vaccines to “bend the curve” and achieve the
declines in incidence and mortality that will be necessary to meet the
time-bound global targets to end TB. Mona Balani (Touched by TB
Coalition, India) reminded the audience of the devastating impact of TB
on individuals, families and communities, and that prevention of TB
should be a priority, and Blessina Kumar (Global Coalition of TB
Activists, India) emphasized that new TB vaccines must be affordable
and accessible to those who most need them, and the importance of
engaging affected communities and civil society in TB vaccine research.
Henk Bekedam (WHO Representative to India, WHO Country Office for
India) made a strong case for investment in TB vaccines as a global
public health good as it would help in accelerating the much needed
“bending of the curve”, and also stressed the need for effective com-
munity engagement. The speakers in these sessions noted that colla-
borations within and across countries, such as the newly formed BRICS
TB Research Network, the India TB Research Consortium, and the
RePORT (Regional Prospective Observational Research on
Tuberculosis) Consortium, can provide new opportunities to share and
leverage knowledge, resources, and learnings to accelerate and advance
TB vaccine R&D; and emphasized the need for increased investment in
and support for TB vaccine R&D.
Fareed Abdullah (Medical Research Council, South Africa), Shelly
Batra (Operation ASHA, India), Michel Kazatchkine (Global Health
Centre, Graduate Institute for International and Development Studies,
Switzerland), Rajiv Modi (Cadila Pharmaceuticals, India), and
Jacqueline Shea (Aeras, USA) contributed to a roundtable discussion
during the final plenary session, providing perspectives on key chal-
lenges, issues and strategies in TB vaccine R&D. They agreed that de-
veloping new TB vaccines is scientifically feasible. It will, however,
require a significant increase in investment and a broader and more
diverse funding base, recognizing that TB is a public health emergency
that requires new models of financing and collective action at a global
level towards which all governments and all sectors must contribute,
and that new TB vaccines must be affordable and accessible. The pa-
nelists also discussed the centrality of new TB vaccines to meeting
global targets to end the TB epidemic, that TB and new TB vaccines
must be placed on the forefront of the global health agenda, and that we
must be stronger and bolder in our advocacy and communications
around TB vaccine R&D.
Lucica Ditiu (Stop TB Partnership, Switzerland), provided the
closing address for the 5th Global Forum on TB Vaccines, noting that
this is a unique and momentous time for TB, with the recent WHO
Ministerial Conference on TB in November 2017 and the upcoming UN
High Level Meeting on TB in September 2018, and she challenged
participants to become advocates, to hold global leaders accountable to
their commitments, and to speak with a united voice to ensure that we
have the financial resources needed to deliver a new and effective TB
vaccine by 2025.
11. Conclusions
The TB vaccine field still has much to do to deliver TB vaccines that
would prevent TB infection and/or disease, as well as accelerate TB
treatment and prevent TB relapse, hopefully also helping to control
drug-resistant tuberculosis. Overall the conclusion of the Forum was
upbeat. Old vaccines are being tested via new routes, such as giving
BCG intravenously; old and new vaccines may be able to prevent in-
fection as well as disease with the first human data being shown in-
dicating that a subunit vaccine expressing just a small number of Mtb
antigens may be able to have protective efficacy; and gene expression
analysis and improved assays measuring mycobacterial growth inhibi-
tion are bringing new insights. It is likely that there will be more focus
in the coming period on progression from infection to disease, and on
how to assess IGRA conversion and reversion.
The next few years will see the results of more TB vaccine clinical
efficacy trials. We hope that at least some of these will induce protec-
tive efficacy, although others will not. Certainly, all will help us better
understand TB; as Barry Bloom (Harvard T. H. Chan School of Public
Health, USA) stated in his Keynote address, “the only vaccine studies
which fail are those from which we fail to learn”. Although the TB
vaccine field receives a fraction of the funds that would be
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commensurate with TB's global disease burden, it is making remarkable
progress.
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